GCP-话题@MedSci

#GCP#

13篇内容 | 1390人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2236434, encodeId=8a7a223643469, content=医肿的GCP中心在李院长的带领下真是越来越好<a href='/topic/show?id=fd4ae8852b' target=_blank style='color:#2F92EE;'>#GCP#</a>, objectTitle=JAMA：医肿GCP中心李宁教授应邀在主刊上发表罕见肿瘤试验社评, objectType=article, longId=850858, objectId=0cd885085807, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20241111/1731317517380_8538692.jpg, objectUrl=/article/show_article.do?id=0cd885085807, replyNumber=0, likeNumber=7, createdTime=2024-11-12, rootId=0, userName=liuyf0307, userId=43812963388, projectId=1, avatar=https://img.medsci.cn/202410/7be9c3cb6d1a4807b2b2f87e7832b635-1qQDmzDzZuNh.jpg, status=1, hasArticle=1, attachment=null, ipAttribution=山东省, moduleDTOList=[ModuleDTO(moduleId=0cd885085807, moduleTitle=JAMA：医肿GCP中心李宁教授应邀在主刊上发表罕见肿瘤试验社评, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0cd885085807)], followStatus=false, userIsMember=true, type=1, lengthMark=0), GetTopicListResponse(id=1294091, encodeId=af8a1294091f6, content=<a href='/topic/show?id=fd4ae8852b' target=_blank style='color:#2F92EE;'>#GCP#</a>, objectTitle=安徽省药监局2020年第1期2020版药物临床试验质量管理规范培训班暨GCP联盟药物临床试验创新技术研究青年委员会成立大会及第一次学术会议直播预告, objectType=article, longId=202979, objectId=487d2029e958, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=487d2029e958, replyNumber=0, likeNumber=50, createdTime=2020-11-08, rootId=0, userName=zhangfenasdf, userId=5fc9246, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=487d2029e958, moduleTitle=安徽省药监局2020年第1期2020版药物临床试验质量管理规范培训班暨GCP联盟药物临床试验创新技术研究青年委员会成立大会及第一次学术会议直播预告, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=487d2029e958)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1294090, encodeId=6a7d1294090fa, content=<a href='/topic/show?id=fd4ae8852b' target=_blank style='color:#2F92EE;'>#GCP#</a>, objectTitle=新版GCP第三十九条解读——受试者、研究者和医疗机构的补偿和保险, objectType=article, longId=194512, objectId=8b96194512cc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8b96194512cc, replyNumber=0, likeNumber=69, createdTime=2020-05-23, rootId=0, userName=zhangfenasdf, userId=5fc9246, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8b96194512cc, moduleTitle=新版GCP第三十九条解读——受试者、研究者和医疗机构的补偿和保险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8b96194512cc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1294089, encodeId=3ad01294089b8, content=<a href='/topic/show?id=fd4ae8852b' target=_blank style='color:#2F92EE;'>#GCP#</a>, objectTitle=实时笔记：我在辉瑞进行GCP培训笔记, objectType=article, longId=172260, objectId=ccc01e226010, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ccc01e226010, replyNumber=0, likeNumber=65, createdTime=2019-06-28, rootId=0, userName=zhangfenasdf, userId=5fc9246, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ccc01e226010, moduleTitle=实时笔记：我在辉瑞进行GCP培训笔记, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ccc01e226010)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1294088, encodeId=6862129408800, content=<a href='/topic/show?id=fd4ae8852b' target=_blank style='color:#2F92EE;'>#GCP#</a>, objectTitle=GCP平台建设，是机遇也是挑战, objectType=article, longId=127721, objectId=a92212e72127, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a92212e72127, replyNumber=0, likeNumber=0, createdTime=2018-01-27, rootId=0, userName=zhangfenasdf, userId=5fc9246, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a92212e72127, moduleTitle=GCP平台建设，是机遇也是挑战, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a92212e72127)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1294087, encodeId=164a129408e7a, content=<a href='/topic/show?id=fd4ae8852b' target=_blank style='color:#2F92EE;'>#GCP#</a>, objectTitle=GMP、GSP、GCP、GLP认证取消基本已定，更严格的动态监管上马！, objectType=article, longId=92036, objectId=dc7a9203654, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dc7a9203654, replyNumber=0, likeNumber=68, createdTime=2017-03-18, rootId=0, userName=zhangfenasdf, userId=5fc9246, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dc7a9203654, moduleTitle=GMP、GSP、GCP、GLP认证取消基本已定，更严格的动态监管上马！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dc7a9203654)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1294086, encodeId=e46912940861a, content=<a href='/topic/show?id=fd4ae8852b' target=_blank style='color:#2F92EE;'>#GCP#</a>, objectTitle=中国医疗器械正进入GCP时代（收藏版）--《医疗器械临床试验质量管理规范》的深度解读, objectType=article, longId=65991, objectId=78aa659917b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=78aa659917b, replyNumber=0, likeNumber=71, createdTime=2016-04-05, rootId=0, userName=zhangfenasdf, userId=5fc9246, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=78aa659917b, moduleTitle=中国医疗器械正进入GCP时代（收藏版）--《医疗器械临床试验质量管理规范》的深度解读, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=78aa659917b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1294085, encodeId=756f1294085ff, content=<a href='/topic/show?id=fd4ae8852b' target=_blank style='color:#2F92EE;'>#GCP#</a>, objectTitle=如何开展新药临床试验：从GCP，SOP到临床试验管理和质量控制, objectType=article, longId=52886, objectId=696d5288694, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=696d5288694, replyNumber=0, likeNumber=55, createdTime=2015-07-06, rootId=0, userName=zhangfenasdf, userId=5fc9246, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=696d5288694, moduleTitle=如何开展新药临床试验：从GCP，SOP到临床试验管理和质量控制, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=696d5288694)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1294084, encodeId=e08c1294084eb, content=<a href='/topic/show?id=fd4ae8852b' target=_blank style='color:#2F92EE;'>#GCP#</a>, objectTitle=Clin Cancer Res：GCP3靶向CAR T细胞HCC治疗潜力, objectType=article, longId=41810, objectId=d76d4181080, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d76d4181080, replyNumber=0, likeNumber=58, createdTime=2014-10-30, rootId=0, userName=zhangfenasdf, userId=5fc9246, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d76d4181080, moduleTitle=Clin Cancer Res：GCP3靶向CAR T细胞HCC治疗潜力, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d76d4181080)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1294083, encodeId=e2301294083ab, content=<a href='/topic/show?id=fd4ae8852b' target=_blank style='color:#2F92EE;'>#GCP#</a>, objectTitle=筹备申报药物临床试验（GCP）机构资格认定的关键环节, objectType=article, longId=31438, objectId=ed1031438a9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ed1031438a9, replyNumber=0, likeNumber=68, createdTime=2014-03-05, rootId=0, userName=zhangfenasdf, userId=5fc9246, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ed1031438a9, moduleTitle=筹备申报药物临床试验（GCP）机构资格认定的关键环节, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ed1031438a9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1294082, encodeId=b35212940828b, content=<a href='/topic/show?id=fd4ae8852b' target=_blank style='color:#2F92EE;'>#GCP#</a>, objectTitle=GCP基础指南中英文双语对照, objectType=article, longId=556, objectId=0b6155601, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0b6155601, replyNumber=0, likeNumber=76, createdTime=2010-07-16, rootId=0, userName=zhangfenasdf, userId=5fc9246, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0b6155601, moduleTitle=GCP基础指南中英文双语对照, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0b6155601)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1294081, encodeId=0830129408140, content=<a href='/topic/show?id=fd4ae8852b' target=_blank style='color:#2F92EE;'>#GCP#</a>, objectTitle=现行的临床研究实施（GCP）规范 (中英对照), objectType=article, longId=553, objectId=59905533f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=59905533f, replyNumber=0, likeNumber=0, createdTime=2010-07-16, rootId=0, userName=zhangfenasdf, userId=5fc9246, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=59905533f, moduleTitle=现行的临床研究实施（GCP）规范 (中英对照), moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=59905533f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1294080, encodeId=74b812940807f, content=<a href='/topic/show?id=fd4ae8852b' target=_blank style='color:#2F92EE;'>#GCP#</a>, objectTitle=GCP的基本原则(中英文对照), objectType=article, longId=551, objectId=25ed55185, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=25ed55185, replyNumber=0, likeNumber=67, createdTime=2010-07-16, rootId=0, userName=zhangfenasdf, userId=5fc9246, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=25ed55185, moduleTitle=GCP的基本原则(中英文对照), moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=25ed55185)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

GCP

2020-05-29

(审核中...)

前往app查看评论内容

医肿的GCP中心在李院长的带领下真是越来越好#GCP#

JAMA：医肿GCP中心李宁教授应邀在主刊上发表罕见肿瘤试验社评

2024-11-12发表于山东省

zhangfenasdf (审核中...)

前往app查看评论内容

#GCP#

安徽省药监局2020年第1期2020版药物临床试验质量管理规范培训班暨GCP联盟药物临床试验创新技术研究青年委员会成立大会及第一次学术会议直播预告

2020-11-08

zhangfenasdf (审核中...)

前往app查看评论内容

#GCP#

新版GCP第三十九条解读——受试者、研究者和医疗机构的补偿和保险

2020-05-23

zhangfenasdf (审核中...)

前往app查看评论内容

#GCP#

实时笔记：我在辉瑞进行GCP培训笔记

2019-06-28

zhangfenasdf (审核中...)

前往app查看评论内容

#GCP#

GCP平台建设，是机遇也是挑战

2018-01-27

zhangfenasdf (审核中...)

前往app查看评论内容

#GCP#

GMP、GSP、GCP、GLP认证取消基本已定，更严格的动态监管上马！

2017-03-18

zhangfenasdf (审核中...)

前往app查看评论内容

#GCP#

中国医疗器械正进入GCP时代（收藏版）--《医疗器械临床试验质量管理规范》的深度解读

2016-04-05

zhangfenasdf (审核中...)

前往app查看评论内容

#GCP#

如何开展新药临床试验：从GCP，SOP到临床试验管理和质量控制

2015-07-06

zhangfenasdf (审核中...)

前往app查看评论内容

#GCP#

Clin Cancer Res：GCP3靶向CAR T细胞HCC治疗潜力

2014-10-30

zhangfenasdf (审核中...)

前往app查看评论内容

#GCP#

筹备申报药物临床试验（GCP）机构资格认定的关键环节

2014-03-05

zhangfenasdf (审核中...)

前往app查看评论内容

#GCP#

GCP基础指南中英文双语对照

2010-07-16

zhangfenasdf (审核中...)

前往app查看评论内容

#GCP#

现行的临床研究实施（GCP）规范 (中英对照)

2010-07-16

zhangfenasdf (审核中...)

前往app查看评论内容

#GCP#

GCP的基本原则(中英文对照)

2010-07-16

科室
- - 订阅+
  - 更多科室
工具
服务